tisagenlecleucel
The overall efficacy of tisagenlecleucel was similar between the two groups. Flu/Cy led to more profound lymphocytopenia ...
The European Commission has approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of ...
The U.S. Food and Drug Administration (FDA) has granted tisagenlecleucel accelerated approval for adult patients with ...
The CAR T-cell therapy was approved for adult follicular lymphoma patients who have received two or more lines of systemic ...
Two adults who received infusions of anti-CD19 CAR T-cell therapy tisagenlecleucel were in remission at nine and ten years.
Tisagenlecleucel was well-tolerated with manageable toxicity in patients with primary central nervous system lymphoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.